Latest From Omeros Corp.
The pipeline for new drug candidates remains healthy as 2019 begins, with almost 40 novel agents already under FDA review. But the chances of another record-breaking year are threatened by a confluence of safety issues that are putting risk management back in the spotlight – and by the widening ripple effects of the recent US government shutdown.
In tandem with Roivant, Cincinnati Children’s launches spinout Aruvant focused on hematologic disorders and separately teams with BridgeBio on genetic disease therapies. Roivant spinout Axovant licenses gene therapy candidates from University of Massachusetts.
Not every drug developer can go public, but biopharma IPOs are launching in multiple markets, including Moderna's prospective $500m US offering and Innovent's $421m Hong Kong IPO. Also, Sarepta prices a $500m FOPO and Omeros sells $210m in notes.
Investors and analysts hope Omeros Corp can explain – and soon - why its candidate drug for treating renal diseases performed only slightly better than placebo in tests on IgA nephropathy patients with high risk of progression, sending the biotech's shares sliding.
- Large Molecule
- Site Specific
- Generic Drugs
- Drug Delivery
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- Neurology, Nervous System
- Renal System
- North America
- Parent & Subsidiaries
- Omeros Corp.
- Senior Management
Gregory A Demopulos, MD, Chmn. & CEO
Timothy M Duffy, PhD, VP, Bus. Dev.
George A Gaitanaris, MD, PhD, CSO
Eckard Leifke, MD, VP, Clin. Dev. & CMO
- Contact Info
Phone: (206) 676-5000
201 Elliott Ave. W.
Seattle, WA 98119
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.